EUCTR2011-004665-32-DE进行中（未招募）不适用
The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- = 18 years of age
- •- Type 2 diabetes
- •- Insulin naïve
- •- Ongoing treatment with metformin or metformin in combination with either sulphonylurea (SU), glinides, dipeptidyl peptidase-IV (DPP-IV) inhibitors or exenatide (only BID)
- •- HbA1c (by central laboratory analysis):
- •- 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy
- •- 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either SU, glinides, DPP-IV inhibitors or exenatide (only BID)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 224
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 96
排除标准
- •- Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks
- •- Calcitonin = 50 pg/mL
- •- Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks
- •- Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)
研究者
相似试验
进行中（未招募）
不适用
The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensificatioMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersDiabetes Mellitus, Type 2EUCTR2011-004665-32-GBovo Nordisk A/S320
进行中（未招募）
不适用
The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification.Diabetes Mellitus Type 2MedDRA version: 15.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-004665-32-ITOVO NORDISK320
尚未招募
2 期
Effects of combination therapy of insulin degludec and oral hypoglycemic agents on hyperglycemia in patients with type 2 diabetes: a randomized controlled studyJPRN-jRCT1031220271Kazuki Orime100
已完成
不适用
Comparison of the efficacy of insulin degludec/insulin aspart and insulin degludec/liraglutide in patients with type 2 diabetestype 2 diabetesJPRN-UMIN000039221Minami Osaka Hospital24
已完成
4 期
The efficacy of insulin degludec/insulin aspart switching from insulin glargine or degludec about glycemic metabolism in type 2 diabetes patientsType 2 diabetesJPRN-UMIN000025199Hokkaido University Hospital60